Zhejiang Boyao Biopharmaceutical

Zhejiang Boyao Biopharmaceutical is a clinical-stage biotechnology company dedicated to the development of innovative immune cell therapies, specifically focusing on next-generation CAR-T cell products. Headquartered in Jiaxing, China, the company utilizes its proprietary technology platforms to engineer T-cells that target hematological malignancies and solid tumors with enhanced precision and durability. Its lead candidate, BY001, is a dual-targeting CAR-T therapy designed to address the challenge of antigen escape in B-cell cancers. Boyao Biopharmaceutical operates a comprehensive R&D center and a GMP-compliant manufacturing facility to support its growing pipeline. By integrating advanced cell engineering with clinical insights, the company aims to provide transformative and accessible treatment options for cancer patients worldwide.